SCHEDULE: Hexstone Capital Discloses 5.6% Stake in Cellectar

Hexstone Capital LLC and Brendan O'Neil have reported a 5.6% beneficial ownership stake in Cellectar Biosciences, Inc., holding 150,000 shares.

Summary

• Hexstone Capital LLC and Brendan O'Neil, as Reporting Persons, have jointly filed a Schedule 13G.
• They beneficially own an aggregate of 150,000 shares of Cellectar Biosciences, Inc. Common Stock.
• This ownership represents 5.6% of the outstanding Common Stock.
• The percentage is calculated based on 2,677,039 shares of Common Stock outstanding following the closing of Cellectar's recent offering.
• The Reporting Persons also hold 150,000 Series A common stock purchase warrants, which are not included in the beneficial ownership calculation due to a 4.99% beneficial ownership limitation ('Blocker') provision.
• The securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a neutral, factual disclosure of a significant passive ownership stake by an institutional investor, which can be viewed as a positive signal of confidence in the company's prospects.

Positives

• A new institutional investor, Hexstone Capital LLC, has taken a significant passive stake, potentially indicating confidence in the company's future prospects.
• The investment is certified as passive, suggesting no immediate intent to influence or disrupt management.

Risks

• The 'Blocker' provision on the Series A common stock purchase warrants limits the immediate exercise of additional shares if it would result in beneficial ownership exceeding 4.99%, which could restrict the investor's ability to increase their stake or influence.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer regarding its operations or financial performance.

Management Comments

• The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

Schedule 13G filings are standard disclosures when an entity acquires more than 5% of a company's shares. For a biotechnology company like Cellectar Biosciences, attracting institutional investment can be a positive signal, especially given the capital-intensive nature of drug development and clinical trials.

Comparison to Industry Standards

• A 5.6% stake represents a significant passive investment for an institutional holder in a small-cap biotechnology company.
• This level of ownership is a notable entry point for an institutional investor, often signaling a long-term view or belief in the company's pipeline or strategic direction.
• The inclusion of a 'Blocker' provision on warrants is a common practice to prevent inadvertent triggering of higher beneficial ownership thresholds that would necessitate a more detailed Schedule 13D filing, which implies an intent to influence or control.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may instill confidence and potentially attract further investment in the company.

Next Steps

• Hexstone Capital LLC and Brendan O'Neil will file subsequent amendments to this Schedule 13G if their beneficial ownership changes significantly.

Key Dates

Recommendation

The filing indicates a new significant passive investment by Hexstone Capital LLC, which could be a positive signal for Cellectar Biosciences. However, as a Schedule 13G, it provides no operational or financial performance updates from the company itself. Investors should hold and await further company-specific news or financial reports to make a more informed decision, while acknowledging the potential positive sentiment from this institutional stake.

Keywords

Cellectar Biosciences, Hexstone Capital, Brendan O'Neil, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Biotechnology, Pharmaceutical, SEC Filing